IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors

IN8bio Announces Pricing of Initial Public Offering